Answer to Question 1
1,3,4,5
Rationale 1: The FDA mission is to protect public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biologic products, medical devices, the nation's food supply, cosmetics, and products that emit radiation.
Rationale 2: It is the role of the U.S. Pharmacopeia (USP) to publish a summary of drug standards (purity and strength).
Rationale 3: Ensuring the availability of effective drugs is one of the FDA's roles.
Rationale 4: It is the FDA's role to take action against any supplement that is deemed to be unsafe.
Rationale 5: It is the role of the FDA to facilitate the availability of safe drugs.
Global Rationale: One of the missions of the CDER branch of the FDA is to improve the health of Americans. It is the role of the U.S. Pharmacopeia (USP) to publish a summary of drug standards (purity and strength). Ensuring the availability of effective drugs is one of the FDA's roles. It is the FDA's role to take action against any supplement that is deemed to be unsafe. It is the role of the FDA to facilitate the availability of safe drugs.
Answer to Question 2
1,2
Rationale 1: During the NDA or the third stage of the drug approval process, the drug's brand name is finalized.
Rationale 2: During the NDA stage of the drug approval process, animal testing may continue.
Rationale 3: Surveying for harmful effects in a larger population occurs during the post-marketing surveillance step of the drug approval process.
Rationale 4: Evaluation of the results of the drug on cultured cells occurs during the preclinical investigation step of the drug approval process.
Rationale 5: Providing the medication to large groups of people with a particular disease occurs during the clinical phase trials, which is in the second stage of the drug approval process.
Global Rationale: During the NDA or the third stage of the drug approval process, the drug's brand name is finalized. Animal testing may continue during this stage. Surveying for harmful effects in a larger population occurs during the post-marketing surveillance step of the drug approval process. Evaluation of the results of the drug on cultured cells occurs during the preclinical investigation step of the drug approval process. Providing the medication to large groups of people with a particular disease occurs during the clinical phase trials, which is in the second stage of the drug approval process.